Abstract: A compact filter element with a large filter surface area having inner and outer rings of filter material with an annular space between them, such that fluid to be filtered can be introduced into the annular space between the rings of filter material and a portion thereof can flow through the outer ring of filter material to the periphery of the filter element and another portion thereof can flow through the inner ring of filter material to the center of the filter element; at least one fluid-permeable support member for the filter material, and at least one end disk on an axial end face of the filter element affixed to the rings of filter material in a sealed manner, in which the end disk has a centrally arranged inlet opening for the fluid to be filtered and one or more radially extending distributor channels leading from the central inlet opening to at least one eccentrically arranged outlet opening which opens into the annular space between the rings of filter material to admit fluid to be filtered to the

Abstract: The present invention provides methods and compositions for the treatment and prevention of neoplasia by administering an effective amount of a NSAID in combination with an effective amount of an immunosuppressant agent. In particular, the present invention provides methods and compositions for the treatment and prevention of neoplasia by administering an effective amount of COX-2 inhibitor in combination with an effective amount of an immunosuppressant agent.

Abstract: An ophthalmic lens (CL), e.g. a contact lens, is centered in a concave trough (10) of an inspection cell (1) which is filled with liquid (W). The inspection cell (10) has a channel (11) which is in communication with the concave trough (10). Centering of the ophthalmic lens is achieved by applying a pulse (P) of a fluid to the liquid (W) so as to whirl up the ophthalmic lens (CL) and by allowing the ophthalmic lens (CL) to settle down in the center of the concave trough (10).

Abstract: The invention relates to a wireless remote control system (100) for vehicle functions (13.1, 13.2), having a portable remote control unit (20) which comprises operator control elements for activating control signals which are exchanged with a vehicle mounted transmitter/receiver unit (11) in order to control the vehicle functions (13.1, 13.2). According to the invention, the remote control unit (20) comprises the following components: at least one first operator control element which has a predefined function of an electronic driving authorization and/or access authorization system (13.2) assigned to it, and at least one second operator control element and at least one display unit for menu prompted control of at least one ride level control system (13.1).

Abstract: Novel indazole derivatives of the formula (I), in which R1-R3 have the meanings indicated in Claim (1), are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.

Abstract: Pyridazine derivatives of the formula (I) act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumors, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.

Abstract: Hydrazono-malonitrile derivatives of the formula (I) in which R1, R2, R3, R3? and R4 have the meanings given in Claim 1 act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumors, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.

Abstract: An apparatus includes a plasma process chamber and a support element capable of supporting a substrate inside the plasma process chamber. At least one plasma control element is placed adjacent to a peripheral portion of the support element such that the plasma control element is capable of influencing a plasma inside the plasma process chamber if an electric field is applied thereto. At least one voltage generator is connected to the plasma control element. The plasma control element is movable inside the process chamber such that it can be set to any of at least two different positions.

Abstract: An antenna orientation sensor, having a base, a pivoting support coupled to the base. An actuator operable to move the pivoting support through a calibration movement with respect to the base. A, for example, three axis magnetic sensor on the pivoting support and a position sensor operable to sense the position of the pivoting support within the calibration movement.

Abstract: Pyrrolopyrimidine derivatives of the formula I in which R3, R4, R5, R6 and X are as defined in claim 1, act as phosphodiesterase VII inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.

Abstract: Novel thienopyridine derivatives of the formula (I), in which R1, R2, R3 and Y have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.

Abstract: Imidazole derivatives of the formula I in which R1 is H, A, benzyl, indan-5-yl, 1,2,3,4-tetrahydronaphthalen-5-yl, dibenzothien-2-yl, or phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, A-CO—NH, benzyloxy, alkoxy, COOH or COOA, R2 is H or A, X is O or S, Hal is F, Cl, Br or I, A is alkyl with 1 to 6 C atoms, and the physiologically acceptable salts and/or solvates thereof as phosphodiesterase VII inhibitors and the use thereof for producing a pharmaceutical.

Abstract: Triazine derivatives of the formula (I) and physiologically acceptable salts and solvates thereof, in which R1, R2, A and R5 are as defined in Claim 1, exhibit phosphodiesterase IV inhibition and can be employed for the treatment of allergic diseases, asthma, chronic bronchitis, atopic dermatitis, psoriasis and other skin diseases, inflammatory diseases, autoimmune diseases, such as, for example, rheumatoid arthritis, multiple sclerosis, Crohn's disease, diabetes mellitus or ulcerative colitis, osteoporosis, transplant rejection reactions, cachexia, tumour growth or tumour metastases, sepsis, memory disorders, atherosclerosis and AIDS, furthermore for inhibiting the formation of TNF?.

Abstract: A method and system for collecting installed application data from a computer system. The method includes scanning a file system of the computer system to produce file system data, and scanning an installed application database of the computer system to produce installed application data. The method further includes collecting system information associated with the computer system. The method still further includes combining the file system data, the application data, and the system information to produce an output file.

Abstract: Aryl oxime derivatives of the formula (I), in which R1, R2, R3, X and B are as defined in Claim 1, act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.

Abstract: Novel phenylquinazoline derivatives of the formula (I), in which R1, R2, R3, R4 and R5 have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.

Abstract: Pharmaceutical proton pump inhibitor (PPI) medications and methods are disclosed for preventing and/or treating gastrointestinal disorders characterized by abnormalities in gastric acid secretion at anytime of the day or night without the need for food effect or to be taken with food. The medications comprise a PPI and a cholinergic agonist for inducing rapid onset of PPI action, for increasing the duration of PPI efficacy and for optimizing clinical PPI effectiveness that may be administered at any time of the day or night without food or on an empty stomach, and possibly on an as-needed or on demand basis. In carrying out the methods, a PPI and cholinergic agonist may be administered together as a single unitary dose in the form of a liquid or solid, or administered together, but separately as either liquids or solids or a combination thereof. Preferably, an oral solid dosage form of the present invention allows for release of a proton pump inhibitor at a pH of about 5 or higher, e.g., pH about 5.5, 6, 6.